5 min
Peter Lio, MD - August 11, 2022 - The New Kids on the Block: IL-13 Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis DermDocs
-
- Education
Peter Lio, MD, LiVDerm faculty and atopic dermatitis expert, shares pearls from his session at the SBS 2022 event regarding the efficacy and safety of IL-13 inhibitors for treatment of AD.
What factors should clinicians consider when selecting a biologic or systemic therapy to manage atopic dermatitis? Effectively and promptly diagnosing atopic dermatitis can be a bit tricky at times. What is your personal approach for effective diagnosis? Which patients would benefit most from an integrative approach to managing atopic dermatitis? How can clinicians execute effective shared decision-making strategies in the management of chronic skin conditions?
Peter Lio, MD, LiVDerm faculty and atopic dermatitis expert, shares pearls from his session at the SBS 2022 event regarding the efficacy and safety of IL-13 inhibitors for treatment of AD.
What factors should clinicians consider when selecting a biologic or systemic therapy to manage atopic dermatitis? Effectively and promptly diagnosing atopic dermatitis can be a bit tricky at times. What is your personal approach for effective diagnosis? Which patients would benefit most from an integrative approach to managing atopic dermatitis? How can clinicians execute effective shared decision-making strategies in the management of chronic skin conditions?
5 min